/stocks — the workspaceLOADING
All PRQR SEC filings, by type → · Earnings date & implied move · Search inside filings
ProQR Therapeutics N.V. (PRQR) is a pharmaceutical preparations company. 1 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind PRQR’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has PRQR been issuing shares? Offering history →
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as PRQR tagged it, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on PRQR plus an auto-SWOT — built from PRQR's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate PRQR using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from PRQR's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentPRQR files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
No fair value band on this page build. No annual filing figures reached the estimators, either because the SEC read did not finish or because PRQR has not filed annual figures yet. That is a statement about the read, not about PRQR’s value. The page rebuilds daily.
Every refusal recorded for PRQR → · How often we decline, and why →
Total return including reinvested dividends, from PRQR’s adjusted closing prices. Past return is not a forecast and not investment advice.
No lawmaker has disclosed a trade in PRQR under the STOCK Act.
No tracked institution reported a position in PRQR in the latest 13F round.
| de Boer Daniel AntonChief Executive Officer | BUY | $354K | view → |
| Filius BartDirector | BUY | $258K | view → |
| de Boer Daniel AntonChief Executive Officer | BUY | $261K | view → |
| de Boer Daniel AntonChief Executive Officer | BUY | $239K | view → |
| Filius BartDirector | BUY | $231K | view → |
1 of the 2 checks that ran found nothing new for PRQR; 1 found something. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Head office: Leiden, Netherlands
Source: the cover page of ProQR Therapeutics N.V.’s 20-F filed 2026-03-12, on EDGAR. Filings checked 2026-10-27. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works